We are live on ! Find out more
GBIO

Generation Bio

Delisted

GBIO was delisted on the 6th of February, 2026.

41 hedge funds and large institutions have $24.2M invested in Generation Bio in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 20 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more capital invested

Capital invested by funds: $13.3M → $24.2M (+$10.9M)

52.74% more ownership

Funds ownership: 6.19%58.93% (+53%)

33% less funds holding

Funds holding: 6141 (-20)

40% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 20

74% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 27

Holders
41
Holders Change
-20
Holders Change %
-32.79%
% of All Funds
0.54%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
7
Increased
12
Reduced
20
Closed
27
Calls
Puts
Net Calls
Net Calls Change

GBIO Hedge Fund Activity: Q3 2025 in Review

41 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q3 2025, worth a combined $24.2M — up 82% from $13.3M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of GBIO and 7 opened new positions — a net loss of 20 holders — while 20 trimmed existing stakes and 12 added.

The largest buyer was Marshall Wace, adding an estimated $1.07M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.4M.

  • 41 institutional investors held Generation Bio (GBIO) as of Q3 2025, down from 61 in Q2 2025.
  • Funds reported $24.2M of Generation Bio stock for Q3 2025, up 82% quarter-over-quarter.
  • 7 funds opened new Generation Bio positions in Q3 2025 and 27 closed out, a net change of -20 holders.
  • The largest Generation Bio buyer in Q3 2025 was Marshall Wace, an estimated $1.07M added.
  • The largest Generation Bio seller in Q3 2025 was T. Rowe Price Associates, an estimated $1.4M sold.

Based on aggregated 13F filings for Q3 2025.